UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 255

Sortiert nach

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Nature medicine, 2010-04, Vol.16 (4), p.460-465

2010

Link zum Volltext

Verfügbarkeit prüfen

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Clinical infectious diseases, 2015-08, Vol.61 (3), p.403-408

2015

Link zum Volltext

Verfügbarkeit prüfen

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

Frontiers in immunology, 2022-04, Vol.13, p.904689-904689

2022

Link zum Volltext

Verfügbarkeit prüfen

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

PloS one, 2016-05, Vol.11 (5), p.e0155406

2016

Link zum Volltext

Verfügbarkeit prüfen

Reassessing oral lead-in for injectable long-acting HIV therapy

The lancet HIV, 2021-11, Vol.8 (11), p.e660-e661

2021

Link zum Volltext

Verfügbarkeit prüfen

High-level dolutegravir resistance selection on dolutegravir/lamivudine

Clinical infectious diseases, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1–Infected Patients with Virological Failure

Clinical infectious diseases, 2010-03, Vol.50 (6), p.872-881

2010

Link zum Volltext

Verfügbarkeit prüfen

Deep molecular characterization of HIV-1 dynamics under suppressive HAART

PLoS pathogens, 2011-10, Vol.7 (10), p.e1002314

2011

Link zum Volltext

Verfügbarkeit prüfen

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

AIDS reviews, 2019-01, Vol.21 (1), p.4-10

2019

Link zum Volltext

Verfügbarkeit prüfen

IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors

Frontiers in immunology, 2023-10, Vol.14, p.1257725-1257725

2023

Link zum Volltext

Verfügbarkeit prüfen

Prevention of Anal Cancer

The New England journal of medicine, 2022-08, Vol.387 (7), p.666

2022

Link zum Volltext

Verfügbarkeit prüfen

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response

Heliyon, 2023-01, Vol.9 (1), p.e12686-e12686, Article e12686

2023

Link zum Volltext

Verfügbarkeit prüfen

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

PloS one, 2014-12, Vol.9 (12), p.e114142-e114142

2014

Link zum Volltext

Verfügbarkeit prüfen

Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study

EClinicalMedicine, 2022-10, Vol.52, p.101600-101600, Article 101600

2022

Link zum Volltext

Verfügbarkeit prüfen

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

AIDS (London), 2013-01, Vol.27 (1), p.81-85

2013

Link zum Volltext

Verfügbarkeit prüfen

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment

PloS one, 2016-02, Vol.11 (2), p.e0149007-e0149007

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

The Lancet (British edition), 2018-03, Vol.391 (10123), p.839-849

2018

Link zum Volltext

Verfügbarkeit prüfen

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

The New England journal of medicine, 2015-08, Vol.373 (9), p.795-807

2015

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees

Frontiers in pediatrics, 2023, Vol.11, p.1353806-1353806

2023

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia

PloS one, 2015-06, Vol.10 (6), p.e0128131

2015

Link zum Volltext

Verfügbarkeit prüfen

Time to get serious with HIV-1 resistance in sub-Saharan Africa

The Lancet infectious diseases, 2017-03, Vol.17 (3), p.241-243

Llibre, Josep M

2017

Link zum Volltext

Verfügbarkeit prüfen

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

PloS one, 2016-07, Vol.11 (7), p.e0159286-e0159286

2016

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees

Frontiers in pediatrics, 2023-01, Vol.10, p.975454-975454

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain

Vaccines (Basel), 2023-12, Vol.12 (1), p.44

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 255

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(248)
Mit Volltextzugriff
(216)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

Reassessing oral lead-in for injectable long-acting HIV therapy

High-level dolutegravir resistance selection on dolutegravir/lamivudine

Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1–Infected Patients with Virological Failure

Deep molecular characterization of HIV-1 dynamics under suppressive HAART

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors

Prevention of Anal Cancer

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

Male genitourinary schistosomiasis-related symptoms among long-term Western African migrants in Spain: a prospective population-based screening study

Corrigendum: Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia

Time to get serious with HIV-1 resistance in sub-Saharan Africa

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees

Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain

Suchergebnisse filtern